BioXcel Therapeutics (BTAI) Cash & Equivalents (2017 - 2026)

BioXcel Therapeutics' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $17.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 44.6% year-over-year to $17.2 million; the TTM figure through Mar 2026 stood at $17.2 million (down 44.6% YoY), while the FY2025 annual figure was $28.4 million, down 4.82% from the prior year.
• Cash & Equivalents was $17.2 million for Q1 2026 at BioXcel Therapeutics, down from $28.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $233.5 million in Q2 2022 to a low of $17.2 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $96.4 million across 5 years, with a median of $65.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents increased 3.31% in 2022, then tumbled 69.02% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $193.7 million in 2022, then sank by 66.33% to $65.2 million in 2023, then slumped by 54.23% to $29.9 million in 2024, then decreased by 4.82% to $28.4 million in 2025, then slumped by 39.54% to $17.2 million in 2026.
• The last three Cash & Equivalents figures came in at $17.2 million (Q1 2026), $28.4 million (Q4 2025), and $36.2 million (Q3 2025), per Business Quant data.